Tardive decrease of astrocytic glutamate transporter protein in transgenic mice with ALS-linked mutant SOD1

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by motor neuron loss.
• Mutations in superoxide dismutase 1 (SOD1) are a known cause of familial ALS.
• Glutamate excitotoxicity, mediated by impaired glutamate transport, is implicated in ALS pathogenesis.

Purpose of the Study:

• To investigate the expression patterns of glutamate transporter proteins EAAT2 and EAAT3 in the spinal cord of a mouse model of ALS.
• To examine the relationship between EAAT2 and GFAP expression in the ventral horn during disease progression.
• To determine the role of EAAT2 in motoneuron degeneration in the G93A SOD1 mouse model.

Main Methods:

• Immunocytochemistry was used to examine the expression of glutamate transporter proteins (EAAT2, EAAT3) and glial fibrillary acidic protein (GFAP) in the spinal cord of G93A SOD1 transgenic mice.
• Expression levels were analyzed at different stages of the disease, including pre-symptomatic, paralytic, and terminal stages.

Main Results:

• Astroglial EAAT2 protein levels were maintained in the ventral horn until the terminal stage of the disease, despite the onset of paralysis.
• Neuronal EAAT3 protein levels decreased concurrently with EAAT2 at the terminal stage.
• Glial fibrillary acidic protein (GFAP) immunoreactivity showed a progressive increase from 25 weeks of age, indicating reactive astrogliosis.
• Dissociative expression patterns between EAAT2 and GFAP were observed in the ventral horn.

Conclusions:

• The findings suggest that EAAT2 is not an early or primary contributor to motoneuron death in the G93A SOD1 mouse model.
• The observed dissociation between EAAT2 and GFAP expression highlights complex glial responses in ALS.
• Further research is needed to elucidate the precise mechanisms of motoneuron degeneration in this ALS model.